SCHEMBL5457822

SCHEMBL5457822

NC(=O)c1c(NC(=O)Nc2ccc(Br)cc2)sc2c1CCOC2

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.59
KCNH2 Q12809 10/20 0.56
FLT3 P36888 1/20 0.52
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
EPHB4 P54760 1/20 0.52
KMT2A Q03164 1/20 0.52
ANO1 Q5XXA6 2/20 0.51
PTPRC P08575 1/20 0.48
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPRB P23467 1/20 0.48
PTPRE P23469 1/20 0.48
TNIK Q9UKE5 1/20 0.48
CXCR2 P25025 2/20 0.46
RAB7A P51149 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16962264 0.90 KCNH2 (0.68) CFTRKCNH2FLT3MEN1NPC1
SCHEMBL5448486 0.89 CXCR2 (0.59) CFTRKCNH2FLT3MEN1KMT2A
SCHEMBL5457888 0.89 ANO1 (0.64) CFTRKCNH2MEN1NPC1RAB9A
SCHEMBL5449304 0.89 CFTR (0.65) CFTRKCNH2FLT3MEN1NPC1
SCHEMBL5455947 0.89 MEN1 (0.65) CFTRKCNH2FLT3MEN1NPC1
SCHEMBL5457654 0.87 CFTR (0.55) CFTRKCNH2FLT3MEN1NPC1
SCHEMBL5460547 0.87 MEN1 (0.58) CFTRKCNH2FLT3MEN1NPC1
SCHEMBL5446177 0.87 CFTR (0.60) CFTRKCNH2FLT3MEN1NPC1
SCHEMBL5453210 0.87 CFTR (0.59) CFTRKCNH2FLT3MEN1NPC1
SCHEMBL5453424 0.86 CFTR (0.59) CFTRKCNH2FLT3MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885KCNH2 3409/4885FLT3 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.